Kim et al., 2011 - Google Patents
High Plasma Concentrations of Transforming Growth Factor-β and Tissue Inhibitor of Metalloproteinase-1–Potential Non-Invasive Predictors for Electroanatomical …Kim et al., 2011
View PDF- Document ID
- 9614336806736211559
- Author
- Kim S
- Park J
- Kim J
- Choi J
- Joung B
- Lee M
- Kim S
- Kim Y
- Pak H
- Publication year
- Publication venue
- Circulation journal
External Links
Snippet
Background: The degree of electroanatomical remodeling of the left atrial (LA) affects the clinical outcome after rhythm control of atrial fibrillation (AF). Our hypothesis was that plasma concentrations of transforming growth factor (TGF)-β and tissue inhibitor of …
- 238000007634 remodeling 0 title abstract description 46
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/1206—Generators therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00636—Sensing and controlling the application of energy
- A61B2018/00696—Controlled or regulated parameters
- A61B2018/0075—Phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00636—Sensing and controlling the application of energy
- A61B2018/00696—Controlled or regulated parameters
- A61B2018/00702—Power or energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | High Plasma Concentrations of Transforming Growth Factor-β and Tissue Inhibitor of Metalloproteinase-1–Potential Non-Invasive Predictors for Electroanatomical Remodeling of Atrium in Patients With Non-Valvular Atrial Fibrillation– | |
| Jansen et al. | Distinct patterns of atrial electrical and structural remodeling in angiotensin II mediated atrial fibrillation | |
| Dobrev et al. | Novel molecular targets for atrial fibrillation therapy | |
| Greener et al. | Connexin43 gene transfer reduces ventricular tachycardia susceptibility after myocardial infarction | |
| Lambiase et al. | Connexins in the heart | |
| Fo et al. | Chronic sigma-1 receptor activation ameliorates ventricular remodeling and decreases susceptibility to ventricular arrhythmias after myocardial infarction in rats | |
| Hasebe et al. | Right-to-left frequency gradient during atrial fibrillation initiated by right atrial ectopies and its augmentation by adenosine triphosphate: Implications of right atrial fibrillation | |
| Onorati et al. | Routine ganglionic plexi ablation during Maze procedure improves hospital and early follow-up results of mitral surgery | |
| Seitz et al. | Active or passive pulmonary vein in atrial fibrillation: is pulmonary vein isolation always essential? | |
| Sousa et al. | Multielectrode mapping for premature ventricular contraction ablation–A prospective, multicenter study | |
| Kim et al. | Electrical remodeling of left atrium is a better predictor for recurrence than structural remodeling in atrial fibrillation patients undergoing radiofrequency catheter ablation | |
| US9907479B2 (en) | Contribution of oxidative stress to AF electrograms | |
| Yan et al. | Chronic catestatin treatment reduces atrial fibrillation susceptibility via improving calcium handling in post-infarction heart failure rats | |
| Lang et al. | Role of Pyk2 in cardiac arrhythmogenesis | |
| Zhu et al. | Effect of angiotensin receptor-neprilysin inhibitor on atrial electrical instability in atrial fibrillation | |
| Pak | Catheter ablation of long-standing persistent atrial fibrillation: a reckless challenge or a way to real cure? | |
| Sohns et al. | Posterior wall substrate modification using optimized and contiguous lesions in patients with atrial fibrillation | |
| Natale et al. | Atrial Fibrillation Ablation, 2011 Update: The State of the Art Based on the VeniceChart International Consensus Document | |
| Kim et al. | Minimal energy requirement for external cardioversion and catheter ablation for long-standing persistent atrial fibrillation | |
| Musiałek | If current inhibition and mortality reduction in heart failure: more than just a ‘pure’effect of lowering heart rate | |
| Tang | Summary (Types of Cardiovascular Diseases, Common Clinical Treatment Methods, and Defects of Cardiovascular Diseases) | |
| Sakata et al. | Assessment of persistent atrial fibrillation arrhythmogenesis in the right atrium using digital twins | |
| Wang et al. | Expression of BRD4 in patients with nonvalvular atrial fibrillation and its role in postoperative recurrence and the development of atrial fibrosis | |
| Manolis et al. | Significant Stagnancy in the Search and Use of New Antiarrhythmic Agents With Some Recent Beams of Hope | |
| Yano et al. | Inflammation and myocardial injury after pulmonary vein isolation with distinct pulsed field ablation modalities: Comparison with thermal ablation |